Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Single-Dose SYM-1219 in Bacterial Vaginosis
NCT02452866Phase 3Completed
- Sponsor
- Symbiomix Therapeutics
- Start
- Jun 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secnidazole in bacterial vaginosis (BV), sponsored by Symbiomix Therapeutics. Primary endpoint: Numbers of Participants With Treatment Emergent Adverse Events and Laboratory Abnormalities at 30 days. Started Jun 2015; status: completed.
02
Drugs
secnidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT02452866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452866.